Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus

被引:0
|
作者
Katsuya Suzuki
Hideto Kameda
Koichi Amano
Hayato Nagasawa
Hirofumi Takei
Eiko Nishi
Ayumi Okuyama
Kensei Tsuzaka
Tsutomu Takeuchi
机构
[1] Saitama Medical University,Division of Rheumatology/Clinical Immunology, Department of Medicine, Saitama Medical Center
[2] Keio University,Division of Rheumatology/Clinical Immunology, Department of Internal Medicine
来源
Rheumatology International | 2011年 / 31卷
关键词
Tacrolimus; Systemic lupus erythematosus; T cell;
D O I
暂无
中图分类号
学科分类号
摘要
The aim of this study was to prospectively evaluate the efficacy and safety of tacrolimus (TAC) in various manifestations of systemic lupus erythematosus (SLE) patients in daily clinical practice. Each of the 21 TAC-treated patients with SLE in our care over 2 years was enrolled in this open-label trial. Patients were administered TAC at a dosage of 1–6 mg once daily, followed up for 24 weeks. Efficacy and safety were evaluated utilizing clinical and laboratory findings. As treatment targets, TAC was preferentially used with oral corticosteroid administration for mild active manifestations such as arthritis, skin eruptions, or asymptomatic nephritis. In efficacy, the mean value of the SLE disease activity index was significantly reduced to 4.1, 2.7, 1.8, and 1.2 (N = 21, 20, 16 and 13) at 0, 4, 12, and 24 weeks, respectively. In eight cases, treatment was discontinued within 24 weeks due to insufficient effects (6 cases) and side effects (2 cases). Non-serious side effects were observed in only five cases (23.8%) over 24 weeks. TAC can be considered both effective and safe for the treatment of various manifestations of SLE.
引用
收藏
页码:757 / 763
页数:6
相关论文
共 50 条
  • [21] Safety and Efficacy of Rituximab in Systemic Lupus Erythematosus
    Terrier, Benjamin
    Amoura, Zahir
    Ravaud, Philippe
    Hachulla, Eric
    Jouenne, Romain
    Combe, Bernard
    Bonnet, Christine
    Cacoub, Patrice
    Cantagrel, Alain
    de Bandt, Michel
    Fain, Olivier
    Fautrel, Bruno
    Gaudin, Philippe
    Godeau, Bertrand
    Harle, Jean-Robert
    Hot, Arnaud
    Kahn, Jean-Emmanuel
    Lambotte, Olivier
    Larroche, Claire
    Leone, Jean
    Meyer, Olivier
    Pallot-Prades, Beatrice
    Pertuiset, Edouard
    Quartier, Pierre
    Schaerverbeke, Thierry
    Sibilia, Jean
    Somogyi, Alexandre
    Soubrier, Martin
    Vignon, Eric
    Bader-Meunier, Brigitte
    Mariette, Xavier
    Gottenberg, Jacques-Eric
    ARTHRITIS AND RHEUMATISM, 2010, 62 (08): : 2458 - 2466
  • [22] ASSOCIATION BETWEEN SAFETY, EFFICACY AND HYDROXYCHLOROQUINE DOSAGE IN THE TREATMENT OF CUTANEOUS LUPUS ERYTHEMATOSUS AND SYSTEMIC LUPUS ERYTHEMATOSUS
    Wakiya, R.
    Kameda, T.
    Lzumikawa, M.
    Nakashima, S.
    Shimada, H.
    Ozaki, H.
    Kondo, A.
    Kadowaki, N.
    Dobashi, H.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1213 - 1213
  • [23] Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE)
    Justin Chan
    Giles D. Walters
    Prianka Puri
    Simon H. Jiang
    BMC Rheumatology, 7
  • [24] Efficacy and safety of multitarget therapy with mizoribine and tacrolimus for systemic lupus erythematosus with or without active nephritis
    Nomura, A.
    Shimizu, H.
    Kishimoto, M.
    Suyama, Y.
    Rokutanda, R.
    Ohara, Y.
    Yamaguchi, K.
    Okada, M.
    LUPUS, 2012, 21 (13) : 1444 - 1449
  • [25] Safety and efficacy of biological agents in the treatment of Systemic Lupus Erythematosus (SLE)
    Chan, Justin
    Walters, Giles D.
    Puri, Prianka
    Jiang, Simon H.
    BMC RHEUMATOLOGY, 2023, 7 (01)
  • [26] Various Ocular Manifestations in Systemic Lupus Erythematosus: A Case Series
    Sharum, Muhammad Hazim
    Rajan, Rajasudha Sawri
    Iqbal, Tajunisah
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (03)
  • [27] Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: A single-center, real-world, retrospective study
    Wang, Dahai
    Shan, Chunrong
    Liu, Jia
    Zhang, Ranran
    Zhu, Guohao
    Gao, Tingting
    Chang, Hong
    Gao, Shan
    Bai, Cui
    Nie, Nana
    Zhang, Qiuye
    Lin, Yi
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [28] Efficacy of discontinuing risedronate for patients with systemic lupus erythematosus: a prospective study
    Ishida, T.
    Yoshida, S.
    Kimura, Y.
    Fujiki, Y.
    Kotani, T.
    Takeuchi, T.
    Makino, S.
    Arawaka, S.
    LUPUS, 2018, 27 (10) : 1636 - 1643
  • [29] Clinical manifestations, immunological features and prognosis of Chinese pediatric systemic lupus erythematosus: A single-center study
    Zhang, Chen-xing
    Cai, Li
    Zhou, Zheng-yu
    Mao, You-ying
    Huang, Hua
    Yin, Lei
    Chen, Tong-xin
    Zhou, Wei
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2019, 22 (06) : 1070 - 1076
  • [30] Clinical manifestations and treatment patterns of systemic lupus erythematosus
    Nair, Sreedharan
    Annavarapu, Sowmya
    Kunhikatta, Vijayanarayana
    Thunga, Girish
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 163 - 163